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Cannabis use is associated with an earlier age of onset of 
psychosis (AOP). However, the reasons for this remain 
debated.  Methods: We applied a Cox proportional hazards 
model to 410 first-episode psychosis patients to investigate 
the association between gender, patterns of cannabis use, 
and AOP.  Results: Patients with a history of cannabis use 
presented with their first episode of psychosis at a younger 
age (mean years = 28.2, SD = 8.0; median years = 27.1) 
than those who never used cannabis (mean years = 31.4, SD 
= 9.9; median years = 30.0; hazard ratio [HR] = 1.42; 95% 
CI: 1.16–1.74; P < .001). This association remained signifi-
cant after controlling for gender (HR = 1.39; 95% CI: 1.11–
1.68; P < .001). Those who had started cannabis at age 15 
or younger had an earlier onset of psychosis (mean years = 
27.0, SD = 6.2; median years = 26.9) than those who had 
started after 15 years (mean years = 29.1, SD = 8.5; median 
years = 27.8; HR = 1.40; 95% CI: 1.06–1.84; P = .050). 
Importantly, subjects who had been using high-potency can-
nabis (skunk-type) every day had the earliest onset (mean 
years = 25.2, SD = 6.3; median years = 24.6) compared 
to never users among all the groups tested (HR = 1.99; 
95% CI: 1.50- 2.65; P < .0001); these daily users of high-
potency cannabis had an onset an average of 6 years earlier 
than that of non-cannabis users.  Conclusions: Daily use, 
especially of high-potency cannabis, drives the earlier onset 
of psychosis in cannabis users.
Key words:  psychotic disorders/age of onset/gender/ 
cannabis/survival plots/drug use/high-potency cannabis
Introduction
Psychotic patients with a history of cannabis use have an 
earlier age of onset of psychosis (AOP) than those with-
out such a history by almost 3 years, as summarized by 
Large et al (2011).1 However, many studies have shown 
that male gender is also associated with a younger age of 
onset of schizophrenia.2–4 Because males are more likely 
to use recreational drugs than females,5,6 this raises the 
question of whether the earlier AOP in cannabis users 
could be confounded by gender.
The age at starting cannabis and subsequent patterns of 
cannabis use may also be relevant as they influence risk of 
psychosis. For example, Arseneault et al (2002) reported 
that the risk of schizophreniform psychosis is greatest 
among those starting early in adolescence.7 A  popular 
idea suggests that this is because the immature brain is 
especially susceptible to the adverse effects of cannabis.8–10 
On the other hand, an Australian survey has suggested 
that AOP is determined by duration of use of cannabis. 
These investigators concluded that the apparent relation-
ship with age of first use of cannabis is an artifact caused 
by those who started earlier having had a longer duration 
of use. Thus, the effect of cannabis use on risk of develop-
ing psychotic disorders and on AOP might be conditional 
on the cumulative effect of cannabis on the individual.11
Evidence compatible with this latter suggestion comes 
from our previous work showing that frequency of can-
nabis use is important in determining risk of psychosis, 
and that use of high potency types of cannabis such as 
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“skunk” carries a higher risk of psychosis.12,13 This is of 
public health importance since high potency types are 
increasing available.14
Given that the current factors, which are influencing 
risk, might also influence AOP, we set out to investigate 
(1) whether the association between cannabis use and 
younger AOP could be explained by the confounding 
effect of male gender and if  not, (2) which aspects of the 
pattern of cannabis use—(a) frequency of use, (b) type of 
cannabis used, and (c) the age at first use—determine the 
association with earlier AOP.
Methods
Participants
As part of the Genetics and Psychosis (GAP) case-con-
trol study,12,13 we approached all patients aged 18–65 years 
who presented with their first episode of psychosis to the 
adult in-patient units of the South London and Maudsley 
NHS Foundation Mental Health Trust between 2005 and 
2010. Patients who met ICD10 criteria (WHO 1992) for 
a diagnosis of nonaffective (F20-F29) and affective (F30-
F33) psychosis, validated by administering the Schedules 
for Clinical Assessment in Neuropsychiatry (SCAN),15 
were invited to participate in the study. The SCAN 
interview was used to elucidate symptoms present in the 
month before assessment. Those cases meeting criteria 
for organic psychosis (F09) were excluded. If  cases were 
too unwell to cooperate, they were recontacted following 
initiation of treatment.
Of the 606 approached, 145 (23%) refused to take part. 
Refusers were more likely to be of black [χ2 (3) = 52.9; P < 
.01] and of male gender [χ2 (1) = 75.3; P < .01] compared 
to those who consented. Therefore, in all the analyses, we 
tested for the potential confounding effect of ethnicity 
and gender. In addition, as part of a qualitative project 
nested in the study, 12 refusers were asked why they did 
not take part in the study; the main reasons were lack of 
interest in the research and the length of our assessment.
Thus, 461 first-episode patients were recruited. 
However, the data we present here are based on the 410 
patients (89.1%) for whom we had complete data on both 
exposure to cannabis and on date of first contact with 
psychiatric services for psychosis. Ninety-two (22.4%) of 
the sample met criteria for Affective Psychosis, the rest 
having Non-Affective Psychosis.
Measures
Sociodemographic data were collected using a standard 
schedule.16 From March 2006, a more detailed history of 
cannabis use was taken by adding to the assessment the 
Cannabis Experience Questionnaire modified version, 
CEQmv.
12 This later addition meant that there were data 
missing on detailed pattern of cannabis use of those par-
ticipants recruited before this (10.9%).
From the CEQmv, we derived detailed information on 
history of use of tobacco, alcohol, cannabis, and other 
illicit drugs. Those who reported that they had used can-
nabis were asked about their age at first use and their 
duration of use (expressed in years).
Cannabis use was recorded as (1) lifetime history of 
cannabis use, ie, had the subject ever used cannabis at any 
point in their lifetime prior to illness onset? (no = 0; yes = 
1); (2) lifetime frequency of cannabis use, ie, the frequency 
that characterized the subject’s most consistent pattern of 
use (none = 0; at week ends or less frequently = 1; every-
day = 2); among the cannabis users, a small proportion 
of subjects (0.5%) reported having used cannabis more 
than 4 days a week, and they were included in the everyday 
category; and (3) type of cannabis used, ie, the type pref-
erentially used by the subject (none = 0; low potency (hash-
type) = 1; high potency (skunk-type = 2). This variable was 
grouped according to the characteristics of the cannabis 
samples seized by the Police in South East London.17 In 
that study, skunk-type cannabis was found to have an aver-
age delta-9-tetrahydrocannabinol (THC) content of 16% 
compared with 4% for hash-type cannabis. In addition, 
skunk-type cannabis may have a greater psychotogenic 
effect than hash also because it contains less cannabidiol 
(CBD), which may have antipsychotic properties.18–21 In 
the London survey, the hash samples had a THC/CBD 
ratio = 1 while the skunk samples had virtually no CBD.17
AOP was defined as the date of first contact with psy-
chiatric services for psychosis. This definition of onset 
was chosen as it is clearly defined, represents the time 
when not just one but a cluster of psychotic symptoms 
had reached the illness threshold (according to ICD10 
criteria), and is the most commonly reported definition 
of illness onset in studies of schizophrenia.4
Statistical Analysis
Stata 12 was used for all analyses. An initial analysis included 
all participants on whom we had information on lifetime 
cannabis use, and the association between any lifetime can-
nabis use, pattern of use, and AOP was investigated.
Since these were longitudinal data, with time to AOP as 
the outcome, survival analyses were used. The results are 
shown graphically in Kaplan-Meier (KM) plots, and Cox 
regression was used for statistical modeling. In the survival 
analyses, the variable AOP was calculated as the time from 
birth to first contact with psychiatric services for psychosis.
It is only possible to make a meaningful distinction 
between “age” and “cohort” in studies that have recruited 
over long periods, ie, decades. In this study, the patients 
were recruited between 2005 and 2010, so age and 
cohort are almost identical; the subjects’ age coincides 
with the AOP (the outcome) in a first-episode psychosis 
cohort. Therefore, in the analyses, we do not adjust for 
“cohorts = age” since this would mean actually adjusting 
for the outcome.
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Finally, the association between the age at which partic-
ipants first used cannabis and their AOP was considered. 
The mean age at first cannabis use was 16.04 years (SD = 
4.3) and the median 16 years; 95% and 99% of the users 
had started, respectively, by age 17 and 24 years. Although 
it might be thought more appropriate to consider age at 
first use as a continuous predictor, examination of its 
effect using several dummy variables by partitioning the 
variable at the quartile points showed that the effect of 
age at first use was not linear with the log-hazard rate 
of psychosis onset. The group starting <15  years was 
associated with an earlier age at onset, while the other 
3 quartiles were similar; therefore, we dichotomized age 
at first use into 2 categories: 1 = younger than 15 years 
(25th percentile) and 0 = 15 years or older. This cutoff  
also reflected the existing literature that indicates an age 
at first use of cannabis younger than 15 years as a criti-
cal window of exposure associated with a greater risk of 
developing psychosis.8,22–26
KM graphs of  survival functions and Nelson-Aalen 
(NA) plots as well a formal numerical test were used to 
assess the assumption of  proportionality required for 
a Cox regression. Associations between potential con-
founders with both AOP and cannabis use were assessed 
using chi-squared tests. Unadjusted Cox proportional 
hazard (PH) regressions were run for each exposure of 
interest (cannabis use, age at first use, cannabis type or 
frequency of  use). These models were then adjusted for 
any significant covariates, along with gender, which was 
specified as a covariate a priori. Cox regression is the 
appropriate technique to use since these are time-to-
event data. A hazard ratio (HR) of  greater than 1 was 
interpreted as corresponding to a younger AOP (higher 
probability of  experiencing a psychotic disorder at a 
particular time point).
Results
Sample Characteristics
Our sample was predominantly male (66%). Totally, 62% 
had used cannabis at some point in their lives. The distri-
bution of the AOP of the whole sample was skewed, with 
the majority of onsets occurring at younger ages (sup-
plementary figure 1). Therefore, we report the AOP with 
both its mean and median values. The mean AOP was 
29.58 (SD = 9.04) years and the median was 27.6 years; 
10% of people had an onset aged 20 years or less, and 
10% (the 90th centile) aged 42 years or older.
Ethnicity [χ2 (3) = 17.3; P = .001], other illicit drugs use 
[χ2 = 98.6 (1); P < .001], and tobacco use [χ2 (1) = 128.35; 
P < .001] were associated with cannabis use (table 1). 
However, we found no association between ethnicity [χ2 
(3) = 1.92; P = .59], tobacco use (z = 1.64; P = .10) or 
other illicit drug use (z = −0.29; P = .76), and AOP.
Gender and Cannabis Use
Males had AOP significantly younger (mean years = 28.8, SD 
= 8.7; median years = 27.3) than females (mean years = 31.2, 
SD = 9.4; median years = 29.3; HR = 1.26; 95% CI: 1.02–
1.56; P = .028). Furthermore, males were more likely to 
have a history of cannabis use [χ2 (1) = 24.5; P < .001] 
than females.
An unadjusted Cox proportional hazards regression 
(n = 410) found a significant relationship between AOP 
and history of  cannabis use. Subjects who used canna-
bis had a significantly higher probability to present with 
their first episode of  psychosis at a younger age (mean 
years = 28.2 y, SD = 8.0; median years = 27.1 y) than 
those who never used it (mean years = 31.4 y, SD = 9.9; 
median years = 30.0 y; HR = 1.42; 95% CI: 1.16–1.74; 
Table 1. Demographics of Patients, According to History of Cannabis Use
History of Cannabis  
Use  (n = 256)
No History of Cannabis 
Use  (n = 154) Test Statistic P  Value
Mean (SD); median age at  
onset of psychosis (y)
28.2 (8.0); 27.1 31.4 (9.9); 30.0 z = 3.13 .001
Gender, n (%)
 Male 194 (75.9) 81 (52.5) χ2 (1) = 24.5 <.001
 Female 62 (24.1) 73 (47.5)
Ethnicity
 White 88 (34.1) 42 (26.9) χ2 (3) = 17.3 .001
 Black African 93 (36.4) 39 (25.6)
 Black Caribbean 47 (18.2) 56 (35.9)
 Other 28 (11.2) 17 (11.6)
Other illicit drugs use
 Never 131 (51.3) 148 (96.7) χ2 (1) = 98.6 <.001
 Yes 125 (48.7) 6 (3.3)
Lifetime tobacco smoking
 Never 25 (10.1) 100 (65.0) χ2 (1) = 128.4 <.001
 Yes 231 (89.9) 54 (35.0)
Note: P values from Mann-Whitney U and chi-squared tests.
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P < .001). This was only slightly attenuated when adjust-
ing for gender and remained significant (HR = 1.39; 95% 
CI: 1.11–1.68; P < .001) table 2. This finding reflects 
the fact that within each gender, cannabis users had an 
earlier onset than nonusers. Moreover, males who used 
cannabis had an earlier onset (mean years = 26.2, SD = 
7.4; median years = 25.7) than females of  the same can-
nabis using status (mean years = 28.7, SD = 9.3; median 
years = 27.9; HR = 1.23; 95% CI: 0.996–1.52) figure 1. 
This effect, however, marginally fell short of  being sta-
tistically significant (P = .054). The interaction between 
gender and history of  cannabis use was not significant 
(P = .28).
NA survival probability plots of age of onset, gender, 
and history of cannabis use were used to assess the pro-
portionality assumption required for a Cox PH model, 
and no violations of this assumption were found.
Type of Cannabis Used and Pattern of Use
Among users, associations were found between gender 
and type of cannabis used (χ2 (1) = 13.33; P < .001) as 
well as frequency of use [χ2 (1) = 24.51; P < .001], male 
subjects being more likely than females to have used can-
nabis daily and to prefer high-potency (skunk-type) can-
nabis. Male subjects were also more likely to have started 
using cannabis at a younger age compared to females 
(males: mean years = 16.1, SD = 4.0; median years = 
15.5; females: mean years = 18.4, SD = 6.8; median years 
= 16.5; z = −2.7; P = .007). Among those with a history 
of cannabis use, the mean duration of use was 9.5 years 
(SD = 7.1); median = 8.1 years. There was no association 
between gender and duration of use (z = 0.26; P = .79).
We investigated associations between the type, and fre-
quency of cannabis use, with AOP. Adjusting for gender, 
and frequency of use (n = 154), patients who preferentially 
used high-potency (skunk-type) cannabis had a signifi-
cantly earlier onset (mean years = 26.7, SD = 6.3; median 
years = 25.2; HR = 1.68; 95% CI: 1.08–2.63; P = .002), 
than patients who used low potency (hash-type) cannabis 
(mean years = 30.1, SD = 9.6; median years = 28.9). In 
the same model, daily cannabis use was associated with 
an earlier AOP (mean years = 27.1, SD = 7.8; median 
years = 25.9; HR = 1.60; 95% CI: 1.11–2.31; P = .011) 
compared to that of occasional cannabis users (mean 
years = 29.8, SD = 9.2; median years = 28.5) table 2. 
This implies that once gender and the type or frequency 
of cannabis use are taken into account (1) use of high-
potency (skunk-type) cannabis and (2) daily use are inde-
pendently associated with earlier AOP.
Those who first used cannabis earlier than age 15 
reported more frequent use [χ2 (1) = 12.5; P < .001] and 
preferential use of high-potency (skunk-type) cannabis 
[χ2 (1) = 5.4; P = .002] than those who began using at age 
15 or older. Earlier age at first use was found to be associ-
ated with an earlier AOP (HR = 1.40; 95% CI: 1.06–1.83; 
P = .002). When adjusting for gender and duration, this 
association remained significant (HR = 1.36; 95% CI: 
1.04–1.80; P = .050) table 2. Thus, among cannabis users 
of the same age, gender, and duration of use, those who 
began using cannabis earlier than 15  years experienced 
psychosis onset at a significantly younger age (figure 2).
However, when gender, type of cannabis used, and 
frequency of use were controlled for (n = 143), the asso-
ciation between age at first use and AOP was no longer 
significant (HR = 1.18; 95% CI: 0.81–1.73) table 2.
23
24
25
26
27
28
29
30
31
32
1
32.0 
(SD 9.6 ;M=31.2)  
29.7 
(SD 8.5;M=28.1) 
28.7 
(SD 9.3; M=27.9)  
26.2  
(SD 7.4-;M=25.7)  
Mean age (yrs) of onset of psychosis by 
 history of cannabis  and gender 
female never users male never users Females who used cannabis males who used cannabis
Fig. 1. This graph illustrates that cannabis use is associated with an earlier age of onset of psychosis in both males and females. Among 
those who never used cannabis, males are still younger than females when they experience their onset of psychosis. SD = standard 
deviation. As the age of onset is not normally distributed, we also report the median age in years (M = median).
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Formal tests of the models described above showed no 
violations of the proportional hazards assumption.
The Effect of Degree of Exposure to Cannabis
Using Kruskal-Wallis test, the median age of  onset of 
psychotic disorders significantly varied [χ2 (4) = 19.99; 
P < .001] when we compared those who never used can-
nabis with the following 4 groups (representing a graded 
degree of  exposure to cannabis): 1 = low potency (hash-
type) at weekends or less; 2 = low potency (hash-type) 
every day; 3 = high potency (skunk-type) at week ends 
or less; 4 = high potency (skunk) every day. Figure  3 
shows a step-wise reduction in mean AOP from those 
who never used cannabis to those who had used high-
potency type cannabis, every day. Those patients who 
used high-potency cannabis daily were on average over 
6 years younger at time of  onset (mean age = 25.2, SD = 
6.3; median years = 24.6) compared to those who never 
used cannabis (mean years = 31.4, SD = 9.9; median 
years = 30.0).
In a final Cox PH model adjusted for gender, we found 
the effect of cannabis use on AOP was driven by a dose 
effect with those who had been using high-potency can-
nabis every day having an earlier onset of developing a 
psychotic disorder at any given time when compared to 
non-cannabis users of the same age and gender (HR = 
1.99; 95% CI: 1.50–2.65; P < .0001). Thus, they had the 
earliest onset among all the groups tested (table 2).
Discussion
The mean age of onset of our sample is consistent with 
those previous first-episode psychosis studies, which 
included subjects who presented up to 65  years of age 
and both nonaffective and affective psychosis, the latter 
known to have an onset at an older age.4
Moreover, our survival analyses confirm the findings 
of Large et al (2011) that patients with a history of can-
nabis use have an AOP on average 3 years younger than 
those who never used cannabis.1 In contrast with of Large 
et al (2011), we found no association between having used 
other drugs or tobacco, or any confounding sociodemo-
graphic variables, and AOP.1,27 However, consistent with 
the literature, males not only had an AOP significantly 
younger than females but were also more likely to have 
used cannabis. So, if  males have an earlier onset and are 
also more likely to use cannabis, is the association between 
cannabis use and early onset just an artifact of gender?
The data reported in figure 1 and in table 2 clearly show 
that the subjects with the earliest AOP are male cannabis 
users. Indeed, the Cox regression analysis, adjusted for 
gender, indicates that subjects with a history of cannabis 
use have a 39% increased hazard of experiencing a psy-
chosis onset at any given time compared to never users 
of the same gender and age. Thus, in line with a Dutch 
study,28 our data suggest an independent effect of both 
gender and cannabis use on AOP and identify male can-
nabis users as the group with the earliest AOP.
Table 2. Effects of Pattern of Cannabis Use on the Hazard for Experiencing Onset of Psychotic Disorder at Any Given Time
Mean (SD); Median (y)  
Age of Onset of Psychosis
Adjusted  
Hazard Ratioa 95% CI P Value
Cannabis use
 Never 31.4 (9.9); 30.0 —
 Yes 28.2 (8.0); 27.1 1.39 1.11–1.68 <.001
Type used independent of frequency of use
 Hash-like (low potency) 30.1 (9.6); 28.9 —
 Skunk-like (high potency) 26.7 (6.3) 25.2 1.68 1.08–2.63 .002
Frequency of use independent of type used
 Less than daily 29.8 (9.2); 28.5 —
 Daily 27.1 (7.8); 25.9 1.60 1.11–2.31 .011
Age at first use of cannabis
 >15 y 29.1 (8.5); 27.8 —
 ≤15 y 27.0 (6.2); 26.9 1.36 1.04–1.80 .050
Age at first use of cannabis independent of  
type used and frequency of use
 >15 y 29.1 (8.5); 27.8 —
 ≤15 y 28.9 (8.2); 27.4 1.18 0.81–1.73 .37
Hazard ratio for the effect of degree of  
exposure to cannabis
 Never used cannabis 31.4 (9.9); 30.0 —
 Hash less than weekly 31.1 (9.5); 29.8 0.90  0.49–1.28 .357
 Hash everyday 29.5 (8.9); 27.4 1.15  0.64–2.09 .624
 Skunk less than weekly 26.5 (7.6); 25.3 1.48  1.17–2.04 .015
 Skunk everyday 25.2 (6.3); 24.6 1.99  1.50–2.65 <.0001
Note: aAll the above HR adjusted for gender.
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Moreover, consistent with evidence that the magnitude 
of the risk is dependent upon the potency of the cannabis 
used and the frequency of use,12,13 we found a differential 
effect of pattern of cannabis use on AOP. Daily use and use 
of high-potency (skunk) cannabis had independent effects 
in bringing further forward the AOP compared to those 
who used infrequently and or low potency (hash) canna-
bis. This indicates that the effect of cannabis use on the 
timing of onset of a psychotic illness is dose dependent, 
an effect consistent with the dose-dependent association 
between cannabis use and risk of developing psychosis.29
The association between cannabis use and risk of psy-
chosis is reported to be greater in those who started using 
cannabis in early adolescence when sensitive brain devel-
opmental processes are taking place.8,10,30,31 Therefore, it 
is plausible that starting cannabis in early adolescence 
might also impact on AOP. Indeed, our findings show 
that patients who had started using cannabis before 
15  years of age had a greater probability of experienc-
ing their onset of psychotic disorder at any given time 
than someone of the same age who started use later (fig-
ure 2). Interestingly, this association remained significant 
when taking into account gender and duration of use but 
disappeared when we controlled for the type of canna-
bis used and the frequency of use. Because patients who 
started using cannabis before age 15 were much more 
likely to be daily users, our data cannot entirely separate 
the effects of age of first cannabis use and frequency of 
use, or, for that matter, age of first use, frequency and 
total accumulated dose. It could be that the more can-
nabis one is exposed to, the greater the risk of psychosis 
(and the earlier the onset) and that the earlier one starts 
using cannabis, the greater scope there is to be exposed.
This latter would be consistent with the data of Stefanis 
et al (2013).11 Nevertheless, unlike them, we did not find that 
duration of cannabis use explained the association between 
early age at first use and AOP. Rather, it was how frequently 
an individual used cannabis and what type they chose to use 
which best predicted the probability of an earlier AOP. Thus, 
our data are the first to clearly indicate that rather than just 
measuring the duration of cannabis use, it is important to 
establish how often and what type of cannabis has been 
used. This provides a better estimate of the effect of can-
nabis use on risk of psychosis and on AOP. This is similar to 
the situation among subjects reporting 10 years of drinking 
alcohol; here the risk of onset of liver disease is more accu-
rately estimated by how often and what individuals drink 
rather than simply their duration of alcohol consumption.
Limitations
One possible limitation is that we used the date of first con-
tact with psychiatric services for a psychotic disorder as the 
estimate for AOP. Many studies have considered such con-
tact as a proxy for date of onset of psychotic disorders.1,4 
Estimating the date of onset of the first psychotic symp-
tom from patients’ self-report is liable to recall bias; in con-
trast, the date of first contact with psychiatric services is 
clearly defined and is the most commonly used definition 
of age at onset, allowing comparisons with other studies.
However, it has been suggested by Compton et al (2009) 
that an earlier age of contact in cannabis users may just 
0.
00
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1.
00
20 30 40 50 60
analysis time
age at 1st use >15 yrs age at 1st use < = 15yrs
Kaplan-Meier survival estimatesDifferences Rates of onset of Psychotic disorders by
                        at first use of cannabis 
Fig. 2. Kaplan–Meier survival curves showing rate (y axis) of onset for participants grouped by age at first use of cannabis. Subjects who 
started using cannabis at age 15 years or younger experience their onset of psychosis (x axis in years) earlier compared with those who 
started using cannabis older than 15 years of age.
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mean that those who have used cannabis become visible 
to services more quickly (ie, have a shorter duration of 
untreated psychosis [DUP]) than those who never used 
cannabis, though the actual age of onset of symptoms 
may not differ. Furthermore, the same authors have sug-
gested that during the period of untreated psychosis, 
before coming in contact with services, some individu-
als may intensify their cannabis use and thus precipitate 
the onset of full-blown psychosis.32 We, therefore, exam-
ined these hypotheses using information that we col-
lected from a subgroup (N = 270) using the Nottingham 
DUP assessment.33 We found no difference in the mean 
(P = .220) and median (P = .839) lengths of DUP, esti-
mated as number of weeks of untreated psychosis, between 
patients who had used cannabis and those who never did. 
Moreover, there was no association between length of 
DUP and frequency of use (P = .420) or type of cannabis 
used (P = .634). Our results are consistent with those of 
Myles et al (2012), which indicate that cannabis use does 
not significantly affect DUP.34 Furthermore, Barnett et al 
(2007) showed that prodromal patients are more likely to 
stop using cannabis if  they experience psychotic symp-
toms rather than continuing or increasing their use.35
Another possible source of  recall bias derives from 
using information on cannabis use based on self-reported 
data. Therefore, in a random sample of  56 cases, we car-
ried out a urine drug screen to test the reliability of  the 
data on current use (up to 4 weeks prior the assessment). 
Of the 56 cases tested, 34 had reported they were not 
current users; 32 of  these (94%) had a negative urinary 
drug screening; only 2 tested positive and these were 
excluded from the analyses.13 Moreover, any such bias is 
likely to underestimate the strength of  the relationship 
we report between cannabis use and age of  onset. Other 
evidence has suggested that asking psychotic patients 
about their use of  cannabis is, at least in some situations, 
more accurate than urine or blood testing.36
Finally, our sample is representative of subjects access-
ing the adult psychiatric services who, therefore, experience 
their AOP between age 18 and 65 years. Thus, we are exclud-
ing those who have their illness onset in the early teens, a 
time when many adolescents are likely to first try cannabis.37
Implications
Many of those who make contact with services for the 
first time and receive a diagnosis of a psychotic disorder 
are still in education or attempting to enter the job market 
and perhaps not yet in a long-term relationship, ie, with-
out important sources of social and emotional stability. 
Consequently, experiencing an earlier AOP may impact 
negatively on their likelihood of achieving their optimum 
level of function. If, by avoiding cannabis use, an individ-
ual’s AOP can be delayed up to 6 years, this could enable 
him/her to finish education and learn some professional 
skills, thus possibly facilitating later recovery.
The greater effect of high-potency cannabis is of sub-
stantial public health importance, as use of such types 
23
24
25
26
27
28
29
30
31
32
1
31.4 
 (SD 9.9;M=30.0)  31.1 
(SD 9.5;M=29.8)  
29.5  
(SD 8.9; M= 27.4) 
26.5 
(SD 7.6;M-=25.3) 
25.2 
(SD 6.3;M=24.6) 
Mean age (yrs) of onset of psychosis  by 
 degree of exposure to cannabis  
never used cannabis hash at week ends or less hash everyday skunk at week ends or less skunk everyday
Fig. 3. This graph illustrates that subjects who never used cannabis experience their first episode of psychosis at the oldest ages (mean 
ages in years) compared to those who used cannabis. In addition, the greater is the degree of exposure to cannabis (cannabis exposure 
scale expressed in type x frequency), the youngest is the mean age of onset of psychotic disorders. SD = standard deviation. As the age of 
onset is not normally distributed, we also report the median age in years (M = median).
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is becoming commoner in many countries.14,38 Indeed, 
it is critical that educational campaigns are developed 
informing young adolescents, particularly males, of their 
risk when using cannabis, especially daily and of the high 
potency types.
Conclusions
We confirm an association between cannabis use and 
earlier AOP and further show this to be independent of 
gender. Moreover, daily cannabis use and the use of high-
potency cannabis are independently associated with a 
significantly higher hazard to make contact with services 
for psychosis at any given time. Finally, a younger age at 
first cannabis use (≤15 years) is associated with a younger 
AOP only in those who had used cannabis daily. All these 
findings support a true effect of cannabis use on AOP, 
which is dose dependent, similar to its effect on risk of 
developing a psychotic disorder.
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Supplementary material is available at http://schizophren
iabulletin.oxfordjournals.org.
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